Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

BLU-701

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Blueprint Medicines, ZAI Lab

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	BLU-945 + BLU-701 Sensitive: D – Preclinical BLU-945 + BLU-701 Sensitive : D	BLU-945 + BLU-701 Sensitive: D – Preclinical BLU-945 + BLU-701 Sensitive : D
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	BLU-945 + BLU-701 Sensitive: D – Preclinical BLU-945 + BLU-701 Sensitive : D	BLU-945 + BLU-701 Sensitive: D – Preclinical BLU-945 + BLU-701 Sensitive : D
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib + BLU-701 Sensitive: D – Preclinical osimertinib + BLU-701 Sensitive : D	osimertinib + BLU-701 Sensitive: D – Preclinical osimertinib + BLU-701 Sensitive : D